P-035 less can be more: targeted embolization of aneurysms in arteriovenous malformations with no subsequent resection
ConclusionAVMs are complex lesions whose natural history and optimal treatment are incompletely understood. For unresectable lesions with aneurysms, targeted aneurysm embolization appears to be safe and effective. More formal analysis of this approach and direct comparison to other forms of treatment are warranted.DisclosuresM. Alexander: None. D. Cooke: None. D. Hallam: None. S. Hetts: None. L. Kim: None. H. Kim: None. B. Ghodke: None. (Source: Journal of NeuroInterventional Surgery)
Source: Journal of NeuroInterventional Surgery - July 26, 2015 Category: Neurosurgery Authors: Alexander, M., Cooke, D., Hallam, D., Hetts, S., Kim, L., Kim, H., Ghodke, B. Tags: SNIS 12th Annual Meeting Oral Poster Abstracts Source Type: research
Glycoprotein IIb/IIIa inhibitors: The resurgence of tirofiban.
Abstract
Glycoprotein (GP) IIb/IIIa inhibitors block platelet aggregation, reducing thrombotic events in acute coronary syndrome. They are most often utilized in patients who likely have an intracoronary thrombus. Tirofiban, eptifibatide, and abciximab are the three GP IIb/IIIa inhibitors approved for use in the United States. Each agent has unique pharmacological properties. They all have a rapid onset and are most often utilized in conjunction with heparin. Tirofiban, in particular, fell out of favor due to inferior dosing with its original Food and Drug Administration (FDA) approved indication, but has ...
Source: Vascular Pharmacology - July 15, 2015 Category: Drugs & Pharmacology Authors: King S, Short M, Harmon C Tags: Vascul Pharmacol Source Type: research
Safety and efficacy of abciximab in older adults undergoing percutaneous coronary intervention
ConclusionAbciximab may not be associated with excess bleeding complications in older patients compared with younger individuals and may be safe to use in older people if indicated. (Source: International Journal of Clinical Practice)
Source: International Journal of Clinical Practice - July 1, 2015 Category: Internal Medicine Authors: R. A. Brown, E. Shantsila, C. Varma, G. Y. H. Lip Tags: Original Paper Source Type: research
Platelet GP IIb-IIIa Receptor Antagonists in Primary Angioplasty: Back to the Future
Abstract
Coronary artery disease and acute myocardial infarction still represent the leading cause of mortality in developed countries. Therefore, great efforts have been made in the last decades to improve reperfusion strategies and adjunctive antithrombotic therapies. In fact, despite optimal epicardial recanalisation, a large proportion of patients still experience impaired reperfusion and in-stent thrombosis. The adjunctive use of glycoprotein (GP) IIb-IIIa inhibitors may certainly contribute in the reduction of such complications, especially when administered in the early phase of infarction. In fa...
Source: Drugs - July 1, 2015 Category: Drugs & Pharmacology Source Type: research
Rheolityc thrombectomy in acute myocardial infarction: Effect on microvascular obstruction, infarct size, and left ventricular remodeling
ConclusionRT in comparison with MTA was more effective in thrombus removal, but it did not reduced significantly the IS and the extent of MVO. However, a trend toward a lower incidence of MVO and a better preservation of LV volumes were found in RT arm. © 2015 Wiley Periodicals, Inc. (Source: Catheterization and Cardiovascular Interventions)
Source: Catheterization and Cardiovascular Interventions - June 24, 2015 Category: Cardiovascular & Thoracic Surgery Authors: Nazario Carrabba, Guido Parodi, Akiko Maehara, Silvia Pradella, Angela Migliorini, Renato Valenti, Vincenzo Comito, Marco Marrani, Luigi Rega, Stefano Colagrande, Gary S. Mintz, David Antoniucci Tags: Coronary Artery Disease Source Type: research
Small change
The hard part was over. A 76-year-old woman presented with a large cavernous aneurysm and a sixth nerve palsy. Despite her age-related arterial tortuosity, placement of a flow diverter and coils went uneventfully. Two steps remained: obtaining a dynaCT scan to evaluate proper apposition of the stent and femoral closure. Unfortunately, because the injector had been improperly loaded, the initial CT scan had to be aborted. This prolonged the procedure by roughly 10 min. By the time we placed the femoral closure device, the general anesthetic had largely worn off and the patient bucked, lifting both legs off the table an...
Source: Journal of NeuroInterventional Surgery - June 11, 2015 Category: Neurosurgery Authors: Albuquerque, F. C. Tags: Editor ' s column Source Type: research
Intracoronary abciximab in diabetic patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.
CONCLUSIONS: In diabetic patients with STEMI undergoing primary PCI, intracoronary abciximab may improve clinical outcomes as compared with standard intravenous use. These findings require confirmation in a dedicated randomized trial.
PMID: 26071862 [PubMed - as supplied by publisher] (Source: Vascular Pharmacology)
Source: Vascular Pharmacology - June 10, 2015 Category: Drugs & Pharmacology Authors: Piccolo R, Eitel I, Galasso G, Iversen AZ, Gu YL, Dominguez-Rodriguez A, de Smet BJ, Mahmoud KD, Abreu-Gonzalez P, Thiele H, Piscione F Tags: Vascul Pharmacol Source Type: research
Safety of Abciximab injection during endovascular treatment of ruptured aneurysms.
CONCLUSION: When the aneurysm is secured, intra-arterial Abciximab injection is a low complication rate treatment modality for thromboembolic events during embolization of cerebral ruptured aneurysm.
PMID: 25964436 [PubMed - as supplied by publisher] (Source: Interventional Neuroradiology)
Source: Interventional Neuroradiology - June 3, 2015 Category: Radiology Tags: Interv Neuroradiol Source Type: research
Adenosine and verapamil for no-reflow during primary percutaneous coronary intervention in people with acute myocardial infarction.
CONCLUSIONS: It is difficult to draw conclusions because of the insufficient quality and quantity of current research studies. We considered the overall risk of bias of included studies to be moderate. Adenosine as treatment for no-reflow during PPCI could reduce angiographic no-reflow (TIMI flow grade < 3) but was found to increase adverse events. What's more, no evidence could be found to suggest that adenosine reduced all-cause mortality, non-fatal myocardial infarction or the incidence of myocardial blush grade 0 to 1. Additionally, the efficacy of verapamil for no-reflow during PPCI could not be analysed because da...
Source: Cochrane Database of Systematic Reviews - May 18, 2015 Category: Journals (General) Authors: Su Q, Nyi TS, Li L Tags: Cochrane Database Syst Rev Source Type: research
Mechanism of action of antiplatelet drugs on decompression sickness in rats: a protective effect of anti-GPIIbIIIa therapy
We examined the effect of several antithrombotic treatments targeting various pathways on DCS outcome: acetyl salicylate, prasugrel, abciximab, and enoxaparin. Rats were randomly assigned to six groups. Groups 1 and 2 were a control nondiving group (C; n = 10) and a control diving group (CD; n = 30). Animals in Groups 3 to 6 were treated before hyperbaric exposure (HBE) with either prasugrel (n = 10), acetyl salicylate (n = 10), enoxaparin (n = 10), or abciximab (n = 10). Blood samples were taken for platelet factor 4 (PF4), thiobarbituric acid reactive substances (TBARS), and von Willebrand factor analysis. Onset of DCS s...
Source: Journal of Applied Physiology - May 15, 2015 Category: Physiology Authors: Lambrechts, K., Pontier, J.-M., Mazur, A., Theron, M., Buzzacott, P., Wang, Q., Belhomme, M., Guerrero, F. Tags: ARTICLES Source Type: research
47. Safety and Effectiveness of Adjunctive Intraarterial Abciximab In the Management of Acute Limb Ischemia
Contemporary endovascular management of acute limb ischemia (ALI) generally consists of tissue plasminogen activator (tPA) based catheter-directed thrombolysis (CDT) with or without percutaneous mechanical thrombectomy (PMT). Although abciximab (Reopro), a GPIIb/IIIa receptor antagonist, is widely utilized in coronary revascularization, its safety and effectiveness in the treatment of ALI is unknown. Here we review our contemporary experience with the endovascular management of ALI and assess the safety and effectiveness of abciximab. (Source: Annals of Vascular Surgery)
Source: Annals of Vascular Surgery - May 1, 2015 Category: Surgery Authors: Gregory G. Salzler, Peter H. Connolly, Darren B. Schneider, Andrew J. Meltzer Source Type: research
Effect of Abciximab Therapy in Patients Undergoing Coronary Angioplasty for Acute ST-Elevation Myocardial Infarction Complicated by Cardiogenic Shock.
CONCLUSIONS: Patients with STEMI complicated by CS undergoing PCI treated with or without abciximab have similar 1-year survival rates; age, final TIMI 0-1 and oro-tracheal intubation are predictors of death.
PMID: 25912694 [PubMed - as supplied by publisher] (Source: Circulation Journal)
Source: Circulation Journal - April 24, 2015 Category: Cardiology Authors: De Felice F, Tomassini F, Fiorilli R, Gagnor A, Parma A, Cerrato E, Musto C, Nazzaro MS, Varbella F, Violini R Tags: Circ J Source Type: research
Glycoprotein IIb/IIIa inhibitors improve mortality after aspiration thrombectomy in patients with ST-segment elevation myocardial infarction
Manual catheter based thrombus aspiration (TA) can reduce distal embolization of thrombus fragments during subsequent balloon inflation or stent placement, with resultant enhanced downstream microvascular function. Evidence from a previous RCT suggests that patients who were randomized to both abciximab and TA had lower infarct size than patients who were randomized to TA or abciximab alone [1]. A recent meta-analysis showed that TA along with primary PCI reduces major adverse cardiovascular events, reinfarction and stent thrombosis, but does not affect 30-day mortality, compared with primary PCI [2]. (Source: Internationa...
Source: International Journal of Cardiology - March 18, 2015 Category: Cardiology Authors: Navkaranbir S. Bajaj, Sameer Ather, Saurabh Gaba, Himanshu Aggarwal, Pankaj Arora, Gopal Ghimire, Vikas Bhatia, Akhil Parashar, Mustafa I. Ahmed, Ali Ahmed, Massoud A. Leesar Tags: Letter to the Editor Source Type: research
A multicenter randomized study to evaluate intracoronary abciximab with the ClearWay catheter to improve outcomes with Lysis (IC ClearLy): trial study design and rationale: Erratum
No abstract available (Source: Journal of Cardiovascular Medicine)
Source: Journal of Cardiovascular Medicine - February 26, 2015 Category: Cardiology Tags: Erratum Source Type: research
How should I treat subacute stent thrombosis in the context of brain haemorrhage with abciximab?
Authors: Martin-Yuste V, Alvarez-Contreras L, Sabaté M, Kelbaek H, Saunamäki K, Jørgensen E, Kocka V
PMID: 25701264 [PubMed - in process] (Source: EuroIntervention)
Source: EuroIntervention - February 25, 2015 Category: Cardiovascular & Thoracic Surgery Tags: EuroIntervention Source Type: research
